Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy
Por:
Talla, A, Azevedo, JLLC, Latif, MB, Enriquez, AB, Sanchez, GP, Pelletier, AN, Bal, SK, Kumari, S, Schuch, V, Ghneim, K, Rhodes, A, Maldarelli, F, Yarchoan, R, Lurain, K, Ramaswami, R, Sharon, E, Hess, BW, D'Amico, L, Martinez-Picado, J, Chomont, N, Lewin, SR, Deeks, SG, Fling, SP, Cheever, MA, Uldrick, TS, Sharma, AA and Sekaly, RP
Publicada:
1 feb 2026
Ahead of Print:
1 feb 2026
Resumen:
Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1-2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGF beta. Furthermore, among the 14 participants tracked to the end of treatment (ranging from 44 to 315 days after therapy initiation), nine display early induction and sustained expression of interferon-stimulated genes (ISGs), antiviral restriction factors and Toll-like receptor (TLR) signaling and a reduction in the HIV reservoir. Mapping these transcriptomic signatures across more than 1,000 public single-cell RNA sequencing datasets reveals that anti-PD-1-induced programs are present in subsets of across subsets of disease states, indicating that some people already display a heightened antiviral state. Together, these findings define immune pathways that help identify PLWH most likely to experience reservoir decay with anti-PD-1 therapy and suggest that sustained ISG activation may contribute to reservoir reduction and prevention of viral rebound upon ART interruption. ClinicalTrials.gov registration: NCT02595866.
Filiaciones:
Talla, A:
Immunasyst, Phoenix, AZ USA
Azevedo, JLLC:
Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA
Latif, MB:
Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA
Enriquez, AB:
Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA
Sanchez, GP:
West Virginia Univ, Dept Biol, Morgantown, WV USA
Pelletier, AN:
RPM Bioinfo Solut, Montreal, PQ, Canada
Bal, SK:
Signios Biosci Inc, Foster City, CA USA
Kumari, S:
Takara Bio USA Inc, San Jose, CA USA
Schuch, V:
Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA USA
Ghneim, K:
Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA
Rhodes, A:
Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia
Maldarelli, F:
NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD USA
Yarchoan, R:
NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD USA
Lurain, K:
Ohio State Univ, Div Hematol, Comprehens Canc Ctr, Columbus, OH USA
Ramaswami, R:
NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD USA
Sharon, E:
Dana Farber Canc Inst, Boston, MA USA
Hess, BW:
Fred Hutchinson Canc Ctr, Seattle, WA USA
D'Amico, L:
Fred Hutchinson Canc Ctr, Seattle, WA USA
:
IrsiCaixa, Barcelona, Spain
CIBERINFEC, Madrid, Spain
Univ Cent Catalunya UVic UCC, Univ Vic, Barcelona, Spain
ICREA, Barcelona, Spain
Chomont, N:
Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada
CHUM, Ctr Rech, Montreal, PQ, Canada
Lewin, SR:
Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia
Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Serv, Melbourne, Vic, Australia
Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia
Monash Univ, Melbourne, Vic, Australia
Deeks, SG:
Univ Calif San Francisco, San Francisco, CA USA
Fling, SP:
Fred Hutchinson Canc Ctr, Seattle, WA USA
Cheever, MA:
Fred Hutchinson Canc Ctr, Seattle, WA USA
Uldrick, TS:
Fred Hutchinson Canc Ctr, Seattle, WA USA
Sharma, AA:
Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA
Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
Sekaly, RP:
Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA
Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
Green Submitted, hybrid
|